Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival

@article{Nishioka2007LowmolecularweightHI,
  title={Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival},
  author={Jennifer Nishioka and Susan Goodin},
  journal={Journal of Oncology Pharmacy Practice},
  year={2007},
  volume={13},
  pages={85 - 97}
}
Objectives. Venous thromboembolism (VTE) occurs more frequently in cancer patients than in non-cancer patients and outcomes are poor in patients with both cancer and thrombosis. Patients with cancer who develop thrombosis are more likely to experience a recurrence of VTE and have increased bleeding complications while receiving oral anticoagulant treatment. The purpose of this paper is to discuss the causes and outcomes of thrombosis in cancer patients, the limitations of warfarin therapy, the… Expand
Anticoagulation Treatment For Prevention Of Recurrent Thromboembolism In Patients With Cancer
TLDR
Low Molecular Weight Heparin will be the most effective and safest method of anticoagulation for prevention of recurrent venous thromboembolism and/or pulmonary embolism in cancer patients. Expand
Administration of low molecular weight heparins for prolonging the survival of patients with cancer
Thromboembolism represents one of the most common causes of mortality and morbidity in cancer patients, and thromboembolic events occur more often in patients with biologically more aggressiveExpand
Management of Venous Thromboembolism and the Potential to Impact Overall Survival in Patients with Cancer
TLDR
C cumulative results from studies in those with VTE versus without VTE suggest that anticoagulation therapy, particularly with low‐molecular‐weight heparins, prevents morbidity and may reduce mortality. Expand
Anti-Metastatic Activities of Heparins
TLDR
Findings regarding heparins may provide a useful framework for research on novel anti-metastatic drugs and imply that cancer patients should be administered LMWHs instead of oral anticoagulants for the prevention and treatment of thromboembolic events. Expand
Parenteral anticoagulation in ambulatory patients with cancer.
TLDR
Overall, heparin appears to have no effect on mortality at 12 months and mortality at 24 months, and Heparin therapy reduces the risk of symptomatic VTE and minor bleeding, while it increases in the risks of major bleeding. Expand
Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism
TLDR
From this analysis, it appears the trajectory of the platelet count and the factors associated with a slower recovery of it, are the main determinants for the occurrence of hemorrhagic complications during VTE treatment in acute leukemia. Expand
Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center
TLDR
It is noted that dose adjusted-anticoagulant therapy may offer a safe and clinical advantageous strategy for the treatment and secondary prevention of recurrent venous thrombosis inThrombocytopenic patients with hematologic malignancies. Expand
Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation.
TLDR
This update of the systematic review is based on the findings of a literature search conducted on 14 December 2017 and found that VKA compared to no VKA likely decreases the incidence of DVT, while the effect of DOACCompared to no DOAC did not rule out a clinically significant increase or decrease in mortality at three months. Expand
Prevention of venous thromboembolism in neurosurgery: a metaanalysis.
TLDR
In a mixed neurosurgical population, LMWH and ICDs are both effective in the prevention of VTE, and isolated high-risk groups may benefit from a combination of prophylactic methods, suggesting the need for a more individualized approach to these patients. Expand
HEPARIN IN HUMAN PLACENTAL DEVELOPMENT AND THE PREVENTION OF PLACENTAL COMPLICATIONS OF PREGNANCY
TLDR
This review examines the possibility that large numbers of pregnant women are presently being treated inappropriately with heparin, a highly-charged macro-molecule that does not cross the placenta in contrast to the potentially teratogenic and fetotoxic oral drug warfarin. Expand
...
1
2
...

References

SHOWING 1-10 OF 68 REFERENCES
Venous Thromboembolism and Cancer: Risks and Outcomes
TLDR
Cancer and its treatments are well‐recognized risk factors for venous thromboembolism (VTE), and patients with cancer and acute VTE who take anticoagulants for an extended period are at increased risk of recurrent VTE and bleeding. Expand
Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism.
  • A. Lee, F. Rickles, +6 authors M. Levine
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
TLDR
The use of dalteparin relative to coumarin derivatives was associated with improved survival in patients with solid tumors who did not have metastatic disease at the time of an acute venous thromboembolic event. Expand
The efficacy and safety of oral anticoagulation in patients with cancer.
TLDR
Oral anticoagulation is safe and effective in the patient with cancer and it is more difficult to sustain a therapeutic INR in the cancer patients and they may need more frequent monitoring to achieve a low complication rate. Expand
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
TLDR
In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thrombosis without increasing therisk of bleeding. Expand
The risk of a venous thrombotic event in lung cancer patients: higher risk for adenocarcinoma than squamous cell carcinoma
TLDR
The risk of venous thrombosis in lung cancer patients is increased 20‐fold compared to the general population and during chemotherapy or radiotherapy and in the presence of metastases the risk is even higher. Expand
Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM).
TLDR
An extensive literature review is conducted to produce evidence-based recommendations to improve perceptions of the magnitude of this risk among Italian medical and surgical oncologists and alert on the new approaches to prophylaxis and treatment of VTE in cancer patients. Expand
The heparins and cancer.
TLDR
This concise review updates recent basic and clinical data on the heparin-cancer link that clarify mechanisms by which HLGAGs regulate the malignant behavior of cells. Expand
Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.
TLDR
A meta-analysis of all available randomized clinical trials where LMWH was compared with UFH in the treatment of venous thromboembolism to estimate the crude treatment effect of LMWH on mortality in cancer patients compared to UFH suggested an inhibitory effect ofLMWH on tumor growth or metastasis, resulting in a beneficial effect on the survival of cancer patients. Expand
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
TLDR
These results confirm that warfarin is associated with a high bleeding rate in patients with venous thromboembolism and cancer, and prolonged treatment with low-molecular-weight heparin may be as effective as oral anticoagulants and may be safer in these cancer patients. Expand
Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
TLDR
These results confirm that warfarin is associated with a high bleeding rate in patients with venous thromboembolism and cancer and that prolonged treatment with low-molecular-weight heparin may be as effective as oral anticoagulants and may be safer in these cancer patients. Expand
...
1
2
3
4
5
...